AMIGOs
Australasian Merkel Cell Carcinoma Interest GroupEnabling access to high quality care for all patients with Merkel Cell Carcinoma
What is Merkel Cell Carcinoma?
Merkel Cell Carcinoma is a rare but highly aggressive neuroendocrine skin cancer
Merkel Cell Carcinoma has the potential to be lethal and appropriate management should be sought immediately through a specialist centre.
Treatment of Merkel Cell Carcinoma often involves several types of therapy such as surgery, radiation, and sometimes systemic medications. Multidisciplinary evaluation of patients with this cancer is critical to determine and carry out a proper treatment plan.
“Many patients and primary care doctors don’t understand the severity of a Merkel Cell Carcinoma diagnosis. Carers and families often don’t appreciate the seriousness of the condition. How could a skin cancer that you have never heard of, give you a deadly problem, unless it is malignant melanoma? Merkel Cell Carcinoma patients need quick referral to specialists at centres of excellence who understand this disease.”
Jonathan Pincus
Chair, Patient Advocacy Group
Newsfeed
A #MerkelCellCarcinoma session will be part of the
@MASC_Trials ASM. Hear from Dr Wen Xu, @SandhuShahneen and MCC immunotherapy 'I-MAT' trial participant, John Mason, in Brisbane this Thursday 23 March👇
The MASC Trials ASM is on Thurs 23 March, Brisbane. If you want to attend, register NOW as we only have 6 seats left before we're booked out! The MASC Trials ASM is a satellite meeting of the Australasian Melanoma Conference, Brisbane, 24-25 March.
https://www.masc.org.au/asm-2023/
A #MerkelCellCarcinoma session will be part of the @MASC_Trials ASM. Hear from Dr Wen Xu, @SandhuShahneen and MCC immunotherapy trial participant, John Mason, at this face-to-face meeting in Brisbane on 23 March 👇
Only two weeks until the MASC Trials Annual Scientific Meeting & we only have 10 seats left before the meeting is booked out! Hear from experts in melanoma & skin cancer clinical trials, in-person at Brisbane Convention & Exhibition Centre, 23 March.
https://www.masc.org.au/asm-2023/
Our new SOCRATES clinical trial aims to determine if a common cholesterol medication can reduce the risk of heart attacks in melanoma patients treated with immunotherapy. Read more: https://www.masc.org.au/cholesterol-medicine-trial/
@MonashVHI @Cabrinihealth @MonashHealth @MonashUni #Melanoma https://twitter.com/10NewsFirstMelb/status/1630096850198855681
#Exclusive: Immunotherapy could be a game-changer for melanoma patients, but the life-saving treatment gives them with a greater risk of heart disease. Melbourne researchers hope a simple cholesterol-lowering pill could reverse the risk and save hundreds of lives | @CaitlinDugan
Mailing address:
AMIGOs
C/O Melanoma and Skin Cancer Trials
553 St Kilda Road
Melbourne, VIC 3004, Australia
General enquiries:
Email: amigos@masc.org.au
Mailing address:
Melanoma and Skin Cancer Trials
553 St Kilda Road
Melbourne, VIC 3004, Australia
General enquiries:
Email: hello@masc.org.au
